For Industry

Public Meeting on Patient-Focused Drug Development for Autism

On May 4, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Autism. FDA is interested in obtaining patient perspectives on the impact of autism on daily life and patient views on treatment approaches.


May 4, 2017


1:00 p.m. - 5:00 p.m.


FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)


To register for this meeting, visit: Public Meeting on Patient-Focused Drug Development for Autism.disclaimer icon

We recommend registering early for the meeting.

Public Docket:

In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 5, 2017.

  • FDA is interested in patient responses to the questions listed in the Federal Register Notice.

  • Access the public docket here: Docket Information

Page Last Updated: 01/31/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English